Acral Fibrochondromyxoid Tumor: A Clinicopathologic and Molecular Genetic Study of 37 Cases
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2024.100599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Carina A Dehner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomic Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana. Hauptthemen laut MEDLINE: Biomarkers, Tumor. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Acral fibrochondromyxoid tumor (AFCMT) is a recently described likely benign mesenchymal neoplasm arising in the distal extremities with distinctive histologic features and a recurrent THBS1::ADGRF5 fusion. We studied an additional 37 cases of AFCMT and expanded on the so-far reported clinicopathologic and molecular findings. Tumors occurred in 21 females and 16 males, ranging in age from 17 to 78 years (median age: 47), and solely involved the hands (24/37, 65%) or feet (13/37, 35%). Histologic examination revealed well-delineated uni- or multinodular tumors with prominent vasculature-rich septa and bland, chondrocyte-like tumor cells set within abundant chondromyxoid stroma. Immunohistochemical studies showed that tumor cells were positive for CD34 (25/27; 93%) and ERG (27/27; 100%), whereas negative for S100 protein (0/31). Molecular analysis revealed evidence of a THBS1::ADGRF5 fusion in 17 of 19 (89%) successfully tested tumors. Clinical follow-up was available in 8 cases (median: 97 months), with multiple local recurrences in 1 case at 276, 312, and 360 months. We conclude that AFCMT is a distinct entity with reproducible morphologic, immunohistochemical, and molecular genetic features that should be differentiated from other similar appearing acral mesenchymal neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomic Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana.
- Robert J Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida; Department of Dermatology, Mayo Clinic, Jacksonville, Florida.
- Mallinckrodt Institute of Radiology, Musculoskeletal Section, Washington University School of Medicine, St. Louis, Missouri.
Zitieren
APA
Dehner, C. A., Pearson, H., Almohsen, S. S., Lo, Y. C., Thangaiah, J. J., Torres-Mora, J., Guo, R. R., Baker, J. C., Folpe, A. L., Alomari, A. K., Dickson, B. C., Billings, S. D., Michal, M., Demicco, E. G., Fritchie, K. J., & Chrisinger, J. S. A. (2024). Acral Fibrochondromyxoid Tumor: A Clinicopathologic and Molecular Genetic Study of 37 Cases. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100599
Vancouver
Dehner CA, Pearson H, Almohsen SS, Lo YC, Thangaiah JJ, Torres-Mora J, et al. Acral Fibrochondromyxoid Tumor: A Clinicopathologic and Molecular Genetic Study of 37 Cases. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100599
BibTeX
@article{Dehner2024,
author = {Dehner, Carina A and Pearson, Hadley and Almohsen, Shahd S and Lo, Ying-Chun and Thangaiah, Judith Jebastin and Torres-Mora, Jorge and Guo, Ruifeng Ray and Baker, Jonathan C and Folpe, Andrew L and Alomari, Ahmed K and Dickson, Brendan C and Billings, Steven D and Michal, Michael and Demicco, Elizabeth G and Fritchie, Karen J and Chrisinger, John S A},
title = {Acral Fibrochondromyxoid Tumor: A Clinicopathologic and Molecular Genetic Study of 37 Cases},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2024.100599}
}
EUVIMED